Purchase Order 36C25022P0336
Award Date
12/2/21
Potential Completion Date
9/30/22
Potential Value
$189K
Federal Agency
Veterans Integrated Service Network 10
Awardee
Travere Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92130, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs has awarded a $236,500.00 firm fixed price contract to Travere Therapeutics, Inc. to provide the pharmaceutical product Chenodal (chenodiol) 250mg. The contract has a period of performance through March 23, 2024 and was not set aside for any specific business category. Travere Therapeutics is a biopharmaceutical company that specializes in rare disease therapies and has received multiple awards from the VA and other government agencies to supply specialty...
This is a firm fixed price purchase order awarded to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) for the supply of the pharmaceutical product CHENODAL 250 MG 6 DOSES. The contract, which has a potential value of $236,500.00, has a completion date of December 30, 2022. Travere Therapeutics holds a General Services Administration (GSA) Schedule contract for...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 awarded a $236,500 firm fixed price purchase order to Travere Therapeutics, Inc. Travere Therapeutics, Inc. Division for the delivery of CHENODAL 250MG (CHENODIOL) pharmaceutical products. Performance will take place in Foster City, California over a one year period ending September 30, 2024. No subcontractors or set aside designations were indicated. This order for chenodiol, a medication...
This federal contract award was made by the Department of Veterans Affairs (VA) to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The $212,584.00 firm fixed-price purchase order is for the delivery of pharmaceutical drugs, with a period of performance ending on September 30, 2025. Travere Therapeutics holds a Federal Supply Schedule (FSS) contract with the VA as well as two Blanket Purchase Agreements (BPAs) specifically covering the procurement...
This federal contract award to Travere Therapeutics, Inc. is for the delivery of the drug Thiola Tiopronin. The contract, valued at $11,125.32, is a firm fixed price delivery order issued against Travere's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the U.S. Department of Veterans Affairs (VA). The award, which does not have a set-aside designation, has an ultimate completion date of August 26, 2024. Travere Therapeutics is a biopharmaceutical company specializing...
The Department of Veterans Affairs (VA) has awarded Travere Therapeutics, Inc. a firm fixed price delivery order to provide THIOLA 100 MG, a pharmaceutical product used to treat rare diseases affecting kidney and liver function. This award is issued against Travere's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the VA, which serves as the primary vehicle for these types of orders. The delivery order has a potential value of $11,125.32 and a completion date of...
This is a federal contract award to Travere Therapeutics, Inc., a biopharmaceutical company, for the delivery of the pharmaceutical product Thiola 100 mg. The contract, valued at $11,125.32, was awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 (VISN 5) on August 26, 2024, with an ultimate completion date of August 27, 2024. The contract is a firm fixed price delivery order issued under Travere's Federal Supply Schedule (FSS) contract with the VA for...
This is a federal contract award issued by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Travere Therapeutics, Inc. The contract is for the delivery of the pharmaceutical product Filspari, with a ceiling value of $11,280.64 and a completion date of December 18, 2024. The contract is a Delivery Order under Travere's Federal Supply Schedule (FSS) contract with the VA for Pharmaceuticals and Drugs (FSS-61-IB). Additionally, Travere holds two...
This federal contract award is a delivery order issued by the Department of Veterans Affairs (VA) to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The contract, valued at $10,888.08, is for the supply of the pharmaceutical drug FILSPARI 200 MG. The contract was awarded through the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), and is a firm fixed-price delivery order with a completion date of June 11, 2025. Travere...
Travere Therapeutics, Inc. has been awarded a $11,125.32 firm fixed price delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to supply Thiola 100 MG pharmaceutical products. The delivery order was issued under Travere's Pharmaceuticals and Drugs GSA Schedule contract (FSS-61-IB) with no set-aside applied, and performance will occur in San Diego, California by March 12, 2024. Travere specializes in developing therapies for...